NEMOLIZUMAB
UNII GN465U8B72

Substance Identification & Data

This profile provides standardized clinical and technical data for Nemolizumab, uniquely identified by the FDA Unique Ingredient Identifier (UNII) GN465U8B72.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 1476039-58-3 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

GN465U8B72

CAS Registry Number

1476039-58-3

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

NEMOLIZUMAB

Official standardized name for this substance within the FDA UNII nomenclature system.

Molecular Formula

GN465U8B72

The specific atomic composition represented as a molecular structure string.

NCI Thesaurus

C170211

National Cancer Institute reference terminology for clinical and research data.

INN ID

10064

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

LM-25

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Nemolizumab. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

NEMOLIZUMAB

NEMOLIZUMAB-ILTO

Common Names & Synonyms

IMMUNOGLOBULIN G2, ANTI-(INTERLEUKIN 31 RECEPTOR A) (HUMAN-MUS MUSCULUS MONOCLONAL CIM331 .GAMMA.-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL CIM331 .KAPPA.-CHAIN, DIMER

IMMUNOGLOBULIN G2-KAPPA, ANTI-(HOMO SAPIENS IL31RA (INTERLEUKIN 31 RECEPTOR SUBUNIT ALPHA)), HUMANIZED MONOCLONAL ANTIBODY GAMMA2 HEAVY CHAIN (1-445) (HUMANIZED VH (HOMO SAPIENS IGHV1-2*02 (83.70%) -(IGHD)-IGHJ5*01) (8.8.14) (1-121) -HOMO SAPIENS IGHG2*01 (CH1 C10>S (135), R12>K (137), E16>G (141), S17>G (142) (122-219), HINGE C4>S (223) (220-231), CH2 H30>Q (268) (232-340), CH3 R11>Q (355), Q98>E (419) (341-445)) (122-445)), (224-214')-DISULFIDE WITH KAPPA LIGHT CHAIN (1'-214') (HUMANIZED V-KAPPA (HOMO SAPIENS IGKV1-39*01 (82.10%) -IGKJ4*01) (6.3.9) (1'-107') -HOMO SAPIENS IGKC*01 (108'-214')); DIMER (227-227:230-230)-BISDISULFIDE

NEMOLIZUMAB [INN]

NEMOLIZUMAB [JAN]

NEMOLIZUMAB [USAN]

NEMOLIZUMAB [WHO-DD]

NEMOLIZUMAB ILTO [WHO-DD]